ArticleFrontiers in global women's health2026
Bacterial vaginosis and specific high-risk human papillomavirus genotype infection: a cross-sectional study in Nairobi, Kenya.
Article in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bacterial vaginosis is significantly associated with a higher risk of high-risk human papillomavirus persistence: a cohort study in Nairobi, Kenya.Frontiers in global women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence indicates that bacterial vaginosis (BV) plays a role in high-risk Human Papillomavirus (hr-HPV) infection. However, the BV/hr-HPV association is still an under-explored concept in Africa, a region overburdened by the highest prevalence of both infections and cervical cancer in the world. Additionally, there is a significant knowledge gap regarding which specific hr-HPV genotypes contribute to this association in Africa. The objective of this study was to investigate whether BV is significantly associated with hr-HPV infection in Africa, with particular emphasis on the specific hr-HPV genotypes contributing to this association. Methods: This publication is based on a cross-sectional analysis of baseline data from an ongoing cohort study. A total of 498 women met the eligibility criteria and were screened for BV, hr-HPV, and cervical lesions at baseline between July 2022 and November 2023. Logistic regression, C Results: The BV infection and hr-HPV infection rates were 24.7% (123/498) and 28.1% (140/498), respectively. Almost one-tenth (49/498) of the enrolled women had BV/hr-HPV coinfection. A significant association between BV and pooled hr-HPV status (inclusive of the HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68 genotypes) was confirmed in this study (aOR = 2.38, 95% CI: 1.48-3.81), Conclusions: BV was found to be significantly associated with pooled hr-HPV status, HPV-39, and HPV-52 infection in Kenyan women. These findings underscore the importance of treating BV promptly, as doing so may help minimize hr-HPV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.